Viatris Views Ophthalmology, Dermatology, and Gastroenterology as Future Pipeline Focus

Equity Analyst

Keonhee Kim

Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris is one of the largest generic drug manufacturers in the world. Viatris' generics business makes up roughly 40% of company's sales and, along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin 

headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. 

Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Viatris. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

The remaining 60% of Viatris’ sales is derived from off-patent branded drugs, including Lipitor, Lyrica, and Norvasc. While macrotrends like the aging population and growing emerging markets can continue to boost sales, we still expect low- to mid-single-digit erosion in the business from pricing and volume headwinds driven from more patients opting generic versions. To combat this, Viatris has identified ophthalmology, dermatology, and gastroenterology as three key therapeutic areas of focus for future innovations. Since these areas are all specialty-driven, a small salesforce can capture a large number of doctors. And a lot of innovations usually come from smaller players, meaning there is not one big leader that Viatris has to displace to gain shares. It launched Tyrvaya, the first and only nasal spray 

for the treatment of dry eye disease at the time of launch, and it expects additional products for dry eye disease going forward. In 2023, it acquired Oyster Point and Famy Life Sciences, two companies that focus on ophthalmology, and we expect additional small tuck-in acquisitions in the three therapeutic areas to fuel its pipeline.

Business Strategy & Outlook

We assign Viatris a no-moat rating because we do not believe the company possesses any structural advantages strong enough to earn excess returns and generate return on invested capital above its cost of capital over the next 10 years. 

While generic drugs were around in the U.S. since the early 20th century, their industry experienced a significant growth following the passage of the 1984 Hatch-Waxman Act. The legislation facilitated the drug application process for generic drug manufacturers by providing them a safe harbor from patent infringement litigation from branded drug manufacturers and allowed the U.S. Food and Drug Administration to approve applications for generic drugs with abbreviated new drug applications. An ANDA requires the applicant to demonstrate its generic drug’s pharmaceutical equivalence and bioequivalence to the reference drug, but it generally does not require preclinical and clinical data to prove safety and effectiveness since it relies on the FDA’s prior approval of the reference drug’s safety and effectiveness. Overall, this legislation paved a much swifter way for generics manufacturers to get their drugs approved compared with a new drug application, which a new branded drug must go through.

The U.S. generic drug industry enjoyed another boost when Congress enacted a series of amendments named the Generic Drug User Fee Amendments (first one passed in 2012, second in 2017 and the latest in 2022), allowing the FDA to collect fees from ANDA applicants to expedite application approval process. The fees (an ANDA fee rate for 2023 was around $240,000) are not meaningful to sway big generic manufacturers away and they also provide additional revenue streams and financial support to the FDA, allowing applications to be approved more quickly and efficiently. 

These regulatory pushes by the U.S. government paved ways for the industry to be highly competitive and be filled with commoditized products, eroding a lot of pricing power that generics manufacturers once had. And although there are a few number of players that make up a relatively healthy share of the generics market, barriers to entry here is quite low, expanding possibilities for firms in the space to face additional competition going forward. This explains the hike in generic dispensing rate (percentage of prescriptions dispensed with a generic rather than a branded reference drug) which grew from 54% to 91% between 2002 and 2019. And while an average of less than 300 ANDAs were approved annually from 1985 to 2012, thanks to these changes, the FDA has averaged around 1,000 ANDA approvals per year over the last five years. 

Beyond government actions, generics manufacturers also face pressures from players within the drug supply chain. The formation of powerful generic sourcing groups and establishment of generic formularies by pharmacy benefit manager enabled drug distributors and drug buyers to effectively negotiate lower generic prices, hurting manufacturers’ margins.

Three large generic sourcing programs that were formed as joint ventures between large wholesalers and drug purchasers—ClarusONE (2016, McKesson and Walmart); Red Oak Sourcing (2013, Cardinal Health and CVS); and Walgreens Boots Alliance Development (2012, AmerisourceBergen and Walgreens)—have acted as additional headwind for generics manufacturers. These entities were created to lower generics acquisition costs through the aggregation of purchasing power and as a result, they can demand higher buy-side discounts and rebates from generics manufacturers, ultimately eating into their profits. They now purchase roughly 80% of all generics sold in the U.S. Additionally, the interchangeability between generics has facilitated the establishment of generic formularies, in which wholesalers can use their purchasing scale to negotiate deeper concessions for placement in the generic sourcing program. As these three players continue to make up a larger portion of generic sourcing in the country and enhance their buying power, generics manufacturers are left with no other choice but to face the burden, resulting in low- to mid-single-digit price erosion in the market year over year.

By our estimate, roughly 40% and 50% of Viatris total sales are derived from generics and off-patent branded drugs, respectively, and both areas are highly susceptible to all the pricing headwinds mentioned above. Viatris has decided to combat this by rationalizing and optimizing its portfolio, carefully deciding which drugs to continue commercializing and which drugs to discontinue. The company opted to exit spaces where it had too many existing players and discontinue small-molecule drugs that are fairly simple to be FDA-approved and to be replicated. Furthermore, Viatris has continued to pursue more opportunities into branded drugs, aiming to launch sizable novel drugs that can have a meaningful impact on the top and bottom lines. Viatris has also sought to expand its presence in complex generics. These drugs typically face limited competition due to a more complicated level of research and development required before reaching commercial stage. Instead of being available in simple oral tablets, which are relatively easy to replicate by competitors, complex generics and biosimilars usually come in injectables, inhalers, and other different forms that pose more challenges to other manufacturers to produce. 

Despite these efforts, we don’t believe Viatris has any structural advantages over other generic manufacturers. It doesn’t have a meaningfully larger number of first-to-file launches compared with other players in the space. And even if it launches a few drugs that are first to market and gain 180-day exclusivity periods in certain products, they are likely to face direct competition as soon as that period expires, leading to significant volume reductions. If Viatris continues to downsize its portfolio of commoditized and easy-to-replicate generic drugs and replace them with more innovative medicines, we could potentially revisit our analysis. For now, we do not believe Viatris earns a moat rating.

None

Economic Moat

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viatris Inc. (NASDAQ:VTRS ) BofA Global Research Global Healthcare Conference September 15, 2022 11:45 AM ET Company Participants Michael Goettler – Chief Executive Officer Rajiv Malik – President Sanjeev Narula – Chief Financial Officer Conference Call Participants Jason Gerberry – BofA Securities Jason Gerberry Well, good day, everybody. Thanks for joining us at the BofA London Healthcare Conference.

Viatris Inc.'s (VTRS) BofA Global Research Global Healthcare Conference Transcript

Apple

Bristol-Myers

FedEx

Intel

Mastercard

Finding stock picks to beat the market are rare finds nowadays. In September stock markets began on downbeat momentum following the S&P 500 rally throughout the summer.

7 Screaming Buy Stock Picks to Beat the September Market Slump

Its top-line troubles could be transient, but there's a risk they won't be.

Is Viatris Stock a Buy Now?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?

Why Is Viatris (VTRS) Down 10% Since Last Earnings Report?

GlaxoSmithKline

Verizon

With all the recent market volatility, there is no shortage of stocks that are looking seemingly cheaper when compared to the closing months of 2021. First up, I'm thinking about adding to the recent spin-off Viatris Inc.

September 2022 Stock Considerations

PITTSBURGH , Sept. 6, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the BofA Global Research Global Healthcare Conference in London on Thursday, September 15, 2022.

Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference

Viatris's total revenue was $4,116.8 million in Q2 2022, down 10.1% year-on-year. Sales of the company's branded medicines have been declining since the formation of Viatris in 2020.

Viatris: 5% Dividend Yield Is A Threat For Investors

Diageo

Paramount Global

Pfizer

Scotts Miracle-Gro

Vanguard S&P 500 ETF

Vanguard High Dividend Yield ETF

The stock market took a nose dive on August 26th, shedding over 3% in some instances on the overall valuation of the stock market. Diageo yields well above the S&P 500 and is a better yield on average than the majority of high quality stocks.

Dividend Stock Watch List: Lanny's September 2022 Edition

Chevron

AT&T

From healthcare to oil and gas to telecom, these stocks can also help diversify your portfolio.

3 of the Best Dividend Stocks to Buy in September

Viatris reported encouraging earnings numbers earlier this month.

This Beaten-Down Dividend Stock Is a Scorching-Hot Buy

Viatris Inc. (NASDAQ: VTRS) reported its second-quarter results on Monday and lowered the revenue outlook for the 2022 fiscal year. Michael Goettler, CEO of Viatris, said that because of strong operational performance, he believes that Viatris can absorb the foreign exchange rate impact within announced ranges.

Should I sell Viatris shares after Q2 results failed to meet revenue expectations?

AbbVie

AmerisourceBergen

Quest Diagnostics

HCA Healthcare

Laboratory

McKesson

Merck

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

10 defensive stocks that can also provide you with growth and dividends over the long term

Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates

Viatris Inc. (NASDAQ:VTRS ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants Bill Szablewski - Head of Global Capital Markets Michael Goettler - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Chris Schott - JPMorgan Umer Raffat - Evercore Gary Nachman - BMO Capital Markets Greg Fraser - Truist Securities Ash Verma - UBS David Amsellem - Piper Sandler Nathan Rich - Goldman Sachs Operator Good morning. My name is Leo, and I'll be your conference operator conference today.

Viatris Inc. (VTRS) CEO Michael Goettler on Q2 2022 Results - Earnings Call Transcript

Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Surpasses Q2 Earnings Estimates

Reports Total Revenues of $4.12 Billion; U.S. GAAP Net Earnings of $314 Million; Adjusted EBITDA of $1.48 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $803 Million; and Free Cash Flow of $719 Million Strong First Half 2022 Cash Flow; Approximately $1.9 Billion of U.S. GAAP Net Cash Provided by Operating Activities and Approximately $1.8 Billion in Free Cash Flow Reaffirms Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] Despite Foreign Exchange Headwinds; Revises Total Revenues Guidance Range Solely to Reflect the Incremental Impact of Foreign Exchange Board of Directors Declares Quarterly Dividend of $0.12 Per Share Pays Down Approximately $1.5 Billion of Debt in the First Half of 2022; on Track with Full Year 2022 Target of Approximately $2 Billion Biocon Biologics Transaction on Track for Close in Second Half of 2022 [1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or a quantitative reconciliation of its 2022 adjusted EBITDA guidance. U.S. GAAP net cash provided by operating activities for 2022 is estimated to be between $3.1 billion and $3.3 billion.

Viatris Reports Strong Second Quarter 2022 Results

Even over the last month, when the S&P 500 has rallied for an 8% gain, Viatris shares have continued their downwards trajectory, declining 5.5% in value.

Viatris Q2 Preview: Can Shares Snap Their Downtrend?

Barrick Gold

Palantir Technologies

Tyson Foods

The three major U.S. equity indexes closed higher Wednesday. The Dow Jones industrials added 1.29%, the S&P 500 increased by 1.56%, and the Nasdaq jumped by 2.59%.

Earnings Previews: Barrick Gold, Palantir, Tyson Foods, Viatris

Viatris is down 40% since the spin-off. Financial metrics are positively increasing as one-time costs of the merger are decreasing. Safe and high dividend yield combined with exceptional free cash flow yield offer a great margin of safety.

Viatris: A Spinoff To Own

Gilead Sciences

These two companies haven't performed well in the market recently, but that could be an opportunity for investors.

2 Cheap Dividend Stocks Yielding More Than 4%

Enbridge

Altria

3 High-Yielding Dividend Stocks With Payout Ratios Over 100%

Billionaires are taking advantage of the weakness in Pfizer and Viatris this year.

Billionaires Are Piling Into These 2 Dividend-Paying Pharma Stocks

Amgen

ImmunityBio

Eli Lilly

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.

7 Best Pharmaceutical Stocks to Buy Now

Citizens Financial Group

These stocks pay a dividend yield of more than 4%.

2 Deeply Discounted Dividend Stocks With High Yields

PITTSBURGH , July 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Chief Executive Officer  Michael Goettler , President  Rajiv Malik , and Chief Financial Officer  Sanjeev Narula  also will host a webcast at 8:30 a.m.

News for Viatris Stock (VTRS)